Galmed Pharmaceuticals

GLMD

Market cap $4.25M

GLMD Hedge Fund Activity: Q1 2026 in Review

16 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2026, worth a combined $71.2K — down 57% from $166K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of GLMD and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.

The largest buyer was XTX Topco, adding an estimated $7.65K. The largest seller was Two Sigma Investments, cutting an estimated $21.6K.

• 16 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2026, down from 17 in Q4 2025.
• Funds reported $71.2K of Galmed Pharmaceuticals stock for Q1 2026, down 57% quarter-over-quarter.
• 0 funds opened new Galmed Pharmaceuticals positions in Q1 2026 and 1 closed out, a net change of -1 holder.
• The largest Galmed Pharmaceuticals buyer in Q1 2026 was XTX Topco, an estimated $7.65K added.
• The largest Galmed Pharmaceuticals seller in Q1 2026 was Two Sigma Investments, an estimated $21.6K sold.

Based on aggregated 13F filings for Q1 2026.